2022 Forecast: Stock analysts break out crystal balls for region’s biggest companies
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s new asthma treatment gets FDA approval
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen reports revenue growth in Q3 but lowers full-year guidance
Sales increases across Amgen’s drug lineup drove increases in revenue and non-GAAP earnings at the Thousand Oaks biotech company during the third quarter, according to its Nov. 2 earnings release, but pandemic issues persist, and the company lowered its revenue guidance for the year. Amgen, one of the largest biotech companies in the world, reported Read More →
Amgen’s investment in Neumora marks a return to neuroscience research
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen goes full speed ahead on biosimilar drugs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen invests $100M in startup pursuing brain treatments
An Amgen-funded biotech company launched Oct. 7, announcing a strategic partnership between the two companies that includes $100 million in funding and global rights to develop and sell some of Amgen’s experimental drugs for neurodegenerative diseases. Thousand Oaks-based Amgen, one of the largest biotech companies in the world, committed $100 million in equity investment to Read More →
Amgen wins patent case
Thousand Oaks-based Amgen had a big win in court on Sept. 20, as a federal court in New Jersey upheld multiple Amgen patents for its psoriasis treatment, Otezla. Amgen filed a patent infringement lawsuit earlier this year against two companies, Sandoz and Zydus Pharmaceuticals, claiming that their generic versions of Otezla infringed upon at least Read More →
